financetom
Business
financetom
/
Business
/
US Senate confirms Cantor Fitzgerald's Lutnick to head Commerce Department
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US Senate confirms Cantor Fitzgerald's Lutnick to head Commerce Department
Feb 18, 2025 4:54 PM

WASHINGTON (Reuters) -The U.S. Senate voted on Tuesday 51-45 to confirm President Donald Trump's nominee Howard Lutnick, the billionaire chairman and CEO of Wall Street firm Cantor Fitzgerald, to run the Commerce Department.

The Commerce Department, which has 47,000 employees, is responsible for U.S. export controls, anti-dumping and anti-subsidy duties, weather forecasting, fisheries, economic data and promotion of investment in the United States. It also has oversight for the $52.7 billion CHIPS and Science semiconductor manufacturing and research subsidy program, and a $42 billion program to expand high-speed broadband to areas with little or no service.

Trump earlier said he had designated Lutnick as the leader of his trade policy. Lutnick told senators he has advised Trump to pursue across-the-board tariffs country-by-country to restore "reciprocity" to America's trading relationships.

Last week, Reuters reported the White House is seeking to renegotiate CHIPS awards and has signaled delays to some upcoming semiconductor disbursements.

Lutnick told senators the CHIPS program is "an excellent downpayment" to rebuild the sector in the U.S., but needs to be reviewed.

Lutnick is worth $1.5 billion, according to Forbes.

Lutnick has said he will review year-old restrictions on firearms exports put in place by former President Joe Biden's administration, aimed at preventing foreign criminal groups from acquiring U.S. guns.

Lutnick wants to improve U.S. access to Canada's largely closed dairy market and would work to protect the U.S. market from fisheries imports from Russia and China.

Senate Commerce Committee chair Ted Cruz said Lutnick will focus on issues including expanding commercial access to wireless spectrum and "will ensure American taxpayer dollars are spent efficiently and that Congress gets 'the benefit of the bargain' on legislation like the CHIPS and Science Act."

Lutnick said last month Chinese AI startup DeepSeek had misappropriated U.S. technology to create a "dirt cheap" AI model and vowed to impose new restrictions on Beijing's technology access.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Porsche downgrades earnings outlook for FY 2024
Porsche downgrades earnings outlook for FY 2024
Jul 9, 2024
July 9 (Reuters) - Porsche Automobil Holding on Tuesday said it has lowered its 2024 group result after tax and expects it in a range of 3.5 billion euros ($3.78 billion) to 5.5 billion euros after Volkswagen updated its forecast. ($1 = 0.9254 euros) ...
VW Group lowers forecast on possible closure of Audi Brussels site, other expenses
VW Group lowers forecast on possible closure of Audi Brussels site, other expenses
Jul 9, 2024
BERLIN (Reuters) -Volkswagen Group lowered its forecast for operating returns on Tuesday to 6.5-7% from 7-7.5% as it announced that the Audi brand was considering closing its Brussels site because of low demand for the electric higher-end cars it produces. Volkswagen Group, Audi's parent company, said that expenses tied to the decision along with other unexpected expenses in the second...
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
Jul 9, 2024
01:39 PM EDT, 07/09/2024 (MT Newswires) -- Athira Pharma ( ATHA ) said Tuesday it has dosed the last patient in the phase 2/3 for fosgonimeton in patients with mild-to-moderate Alzheimer's disease. The company aims to release top-line results by the end of Q3 and present the full data set on Oct. 29. The trial is studying fosgonimeton in approximately...
Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial
Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial
Jul 9, 2024
01:40 PM EDT, 07/09/2024 (MT Newswires) -- Q32 Bio ( QTTB ) said Tuesday it has completed enrollment in the SIGNAL-AD Phase 2 trial of bempikibart for the treatment of persistent, moderate-to-severe atopic dermatitis in adult patients. The trial enrolled 121 patients, exceeding the initial target of 100, the firm said. Topline data is expected in Q4. Price: 18.88, Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved